Overweight and obese men with prostate cancer are at an increased risk of disease
recurrence, exacerbated treatment-related adverse effects, development of obesity-related …

Androgen deprivation therapy (ADT) has been the main management strategy for prostate
cancer for more than eight decades, nowadays achieved commonly by administration of …

Androgen deprivation therapy continues to be widely used for the treatment of prostate
cancer despite the appearance of new‐generation androgen‐receptor targeting drugs after …

Androgen-deprivation therapy (ADT) entails lowering serum testosterone levels to castrate
levels and forms a cornerstone of the management of hormone-sensitive advanced prostate …

Simple Summary Prostate cancer is the second most diagnosed cancer in men. It is driven
by the male hormone testosterone, and measures used to block testosterone commonly …

Prostate cancer is the most common cancer among men and androgen deprivation therapy
(ADT) is the most effective treatment for this disease. The cornerstone of the treatment of …

Prostate cancer is the most common form of cancer diagnosed in men. Androgen
deprivation therapy (ADT) is commonly prescribed, with some estimates indicating over 50 …

Metabolic syndrome (MS) is one of the leading risk factors for the development of some
common cancers (endometrial cancer, postmenopausal breast cancer, colorectal cancer) …

Background Men receiving androgen deprivation therapy (ADT) for prostate cancer (PC) are
at risk for cardiovascular comorbidities and cognitive changes. Interventional research …

Therapeutic intervention for prostate cancer mostly relies on eliminating circulating
androgen or antagonizing its effect at the cellular level. As the use of endocrine therapies …